Home Dementias Jennifer Brusstar - President & CEO - Tug McGraw Foundation - Discussing... Dementias Jennifer Brusstar – President & CEO – Tug McGraw Foundation – Discussing Brain Cancer, PTSD, and Traumatic Brain Injury By wordpressadmin January 22, 2021 0 23 Facebook Twitter Pinterest WhatsApp submitted by /u/ObjectiveGround5 [comments] Continue Reading to the Source Facebook Twitter Pinterest WhatsApp Previous articleplease help us fundraise (501c3 non-profit) : braincancerNext articleTerrarium Making Workshop – Brain Tumour Society (Singapore) Limited wordpressadmin RELATED ARTICLES Dementias He got his last chemo on Saturday. The same day MRI showed that cancer is back. 8-10 new spots. In only 3 months since... wordpressadmin - February 23, 2021 0 submitted by /u/szejdy Continue Reading to the Source Read more Dementias ITS NOT A TUMOR wordpressadmin - February 19, 2021 0 submitted by /u/WeirdlyTechnical Continue Reading to the Source Read more Dementias Living Through Covid-19 as a Cancer Patient or Survivor wordpressadmin - February 15, 2021 0 https://www.cancertalkfoundation.org/post/living-through-covid-19-as-a-cancer-patient-or-survivor submitted by /u/CancerTalkFoundation Continue Reading to the Source Read more LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Save my name, email, and website in this browser for the next time I comment. Most Popular Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER Alzheimer’s Disease wordpressadmin - February 25, 2021 0 Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that... Read more Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC Alzheimer’s Disease wordpressadmin - February 24, 2021 0 Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell... Read more PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer Alzheimer’s Disease wordpressadmin - February 24, 2021 0 A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is... Read more FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC Alzheimer’s Disease wordpressadmin - February 24, 2021 0 The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and... Read more Load more Recent Comments A WordPress Commenter on Hello world!